Toronto, Ontario – The Newswire – July 18, 2023 - Ventripoint Diagnostics Ltd. ("Ventripoint" or the "Company"), (TSXV:VPT) (OTC:VPTDF) is pleased to announce that Freiburg Hospital has chosen to adopt the VMS+ as its cardiac diagnostic tool.  

The University Medical Centre Freiburg im Breisgau, Germany, is notably one of the largest hospitals in Europe and is recognized as the supra-regional centre for the treatment of complicated heart disease. It treats approximately 90,000 inpatients and 897,000 outpatients annually.

Dr. Alvira Macanovic, Ventripoint’s President and CEO stated, “This year the Ventripoint team is laser-focused on sales growth and this sale to a leading institution in Europe is indicative of the sales momentum and traction we are seeing in one of our key markets through the cooperative efforts of our direct sales team, channel partners, and trial teams.  

The VMS+ will be utilized by the department of congenital heart defects and paediatric cardiology who treat 4,000+ children, youth, and young adults with congenital and acquired heart diseases each year. With the VMS+, the cardiac medical centre will be able to make its diagnostic and procedural decisions more efficiently and quickly, leading to better outcomes for patients. The VMS+ will serve as an adjunct to speed up decision-making in patient treatment and as an alternative to cardiac MRI when a patient is contraindicated.  Most importantly, VMS+ will be used to aid in diagnosis and in continuous monitoring of patients throughout their journey as performing a VMS+ study fits normal scanning workflows.  The VMS+ will also be used to assist in the research of terminal heart failure and mechanical cardiovascular replacement and in pediatric drug trials for congenital heart defects.

Sales, installation and support of the VMS+ in Europe is handled by Angiopro GmbH. The cooperation between Ventripoint and Angiopro ensures optimal customer service, so that all VMS+ users can rely on intensive and timely support.

Ventripoint is committed to elevating cardiac care through innovative products like the VMS+ and will continue to work with healthcare professionals and institutions to develop solutions that improve the patient care journey.

About Ventripoint Diagnostics Ltd.

Ventripoint has become an industry leader in the application of AI (Artificial Intelligence) to echocardiography. Ventripoint's VMS products are powered by its proprietary KBR technology, which is the result of a decade of development and provides accurate volumetric cardiac measurements equivalent to MRI. This affordable, gold-standard alternative allows cardiologists greater confidence in the management of their patients. Providing better care to patients serves as a springboard and basic standard for all of Ventripoint's products that guide our future developments. In addition, VMS+ is versatile and can be used with all ultrasound systems from any vendor supported by regulatory market approvals in the U.S., Europe and Canada.

For further information, please contact:

Jonathan Robinson CFA

JRobinson@oakhillfinancial.ca

(416) 669-1001

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release.

About Angiopro GmbH

Angiopro is a classic distributor company with headquarters in Speyer, Rhineland-Palatinate. The company portfolio includes the distribution of vascular medical devices as well as the world's leading software in patient screening before and after cardiovascular interventions. Website: www.angiopro.de

About Medical Center – University of Freiburg

With roughly 15,000 employees, the Medical Center – University of Freiburg is among the largest university medical centers in Germany. Around 1,800 doctors and more than 4,300 nurses provide care to more than 90,000 inpatients and around 900,000 outpatients per year.

The Medical Center – University of Freiburg engages in research, teaching, and healthcare as its core responsibilities, always with the goal of offering its patients treatment informed by the latest scientific findings – today and in the future.

Forward Looking Statements

This news release contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. The use of any of the words "expect", "anticipate", "continue", "estimate", "objective", "ongoing", "may", "will", "project", "should", "believe", "plans", "intends'' and similar expressions are intended to identify forward-looking information or statements. The forward-looking statements and information are based on certain key expectations and assumptions made by the Company. Although the Company believes that the expectations and assumptions on which such forward-looking statements and information are based are reasonable, undue reliance should not be placed on the forward-looking statements and information because the Company can give no assurance that they will prove to be correct.

Since forward-looking statements and information address future events and conditions, by their very nature they involve inherent risks and uncertainties. Actual results could differ materially from those currently anticipated due to a number of factors and risks. Factors which could materially affect such forward-looking information are described in the risk factors in the Company's most recent annual management's discussion and analysis that is available on the Company's profile on SEDAR at www.sedar.com. Readers are cautioned that the foregoing list of factors is not exhaustive. The forward-looking statements included in this news release are expressly qualified by this cautionary statement. The forward-looking statements and information contained in this news release are made as of the date hereof and the Company undertakes no obligation to update publicly or revise any forward-looking statements or information, whether as a result of new information, future events or otherwise, unless so required by applicable securities laws.